Skip to main content

Table 1

From: Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study

 

HCV

BASAL

48-WEEK

Δw48-w0

P(Δw48-w0)

BMI (Kg/m2)

-

24.5 (22-27)

26 (23-29)

0.34 (-1.0-+0.9)

>.05

 

+

22 (20-26)

20 (18-23)

-0.35 (-0.8-+1.2)

>.05

Fasting glucose (mg/dl)

-

87 (83-97)

88 (85-95)

-0.5 (-5.7-+8)

>.05

 

+

94 (83-103)

90 (80-105)

+2 (-24-+12)

>.05

HOMA

-

1 (0.8-3.6)

1.4 (0.9-3.2)

-0.06 (-1.5-+0.8)

>.05

 

+

3.5 (1.8-6.3)

4.5 (3-7.5)

+1.8 (-4.6-+3.1)

>.05

TC (mg/dl)

-

197 (165-215)

179 (161-200)

-18 (-40- -3)

.02

 

+

157 (132-174)

144 (127-165)

-5 (-32-+15)

>.05

TG (mg/dl)

-

149 (122-241)

126 (101-208)

-10 (-92-+17)

>.05

 

+

139 (99-186)

114 (89-197)

0 (-19-+59)

>.05

  1. As Median (Interquartile range). In all comparisons between HCV- vs HCV+ p > .05